Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
about
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesIn-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for NeuroradiologistsImproved localisation for 2-hydroxyglutarate detection at 3T using long-TE semi-LASERNon-invasive metabolic imaging of brain tumours in the era of precision medicine.Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo.Detecting tumor progression in glioma: Current standards and new techniques.Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization.Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant GliomaDeep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma.Long Noncoding RNA miR210HG as a Potential Biomarker for the Diagnosis of Glioma.An Update on the Approach to the Imaging of Brain Tumors.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Imaging Tumor Metabolism to Assess Disease Progression and Treatment Response.Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Academic Cancer Center Phase I Program Development.Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.MRI radiomics analysis of molecular alterations in low-grade gliomas.Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy.Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma.The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas.Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.Glycine: a non-invasive imaging biomarker to aid magnetic resonance spectroscopy in the prediction of survival in paediatric brain tumours.Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
P2860
Q28066926-CFB82E6A-4152-45FE-A949-368937249255Q28069062-C414099D-401D-4B33-8490-E36D57C5A7FDQ28829812-C45DD1CB-FA52-47B8-B7C3-21044973CFF8Q31115540-565BA7BE-E9FC-44B1-9626-0D14A1648BB3Q31117278-8400B685-1F0C-43DA-9CA4-ACB8D2D5E3D4Q31132701-F6DE0E94-0B8E-4E42-B8FA-40FB5C5B997EQ31154376-47A8C495-AC94-4208-83F9-7352067C3626Q33816600-A215B70A-F06B-4B49-BDCF-27A8AFE72F42Q33906012-FE4A4511-EA5E-498C-A787-5068F82D2A58Q36145810-93FAF4D0-FD81-4D3D-9042-7ED3E43E5045Q36374577-6256C0AF-2593-4544-95D2-F293BC0295D4Q36805635-1FDEFBC2-D1A7-4A1B-9C52-0242E238D454Q38949887-C90480BD-CFDA-4501-A1DD-8244CAD4AAB2Q38961789-80504C12-C9DC-4596-A33B-8AFD753959FEQ39383501-13437B24-1A05-420F-A2FE-8D691122C21BQ39639152-AB6ADBD0-A482-4605-8DB9-FB281496D679Q40281311-D09A0125-41FC-4559-8763-A2E81FBEE4E3Q41026412-CB7C5FCB-7984-46D2-A4DB-A1A946D4BA32Q42046541-E141ECAC-CFB3-4749-A469-585D4BF2F1E5Q42702320-60EF3B85-D464-4FB9-945C-735FFA8CDC07Q42702324-5EC6B4AE-BDCD-4427-AFB2-743E6C7086CAQ47605895-343B9E8F-6898-422D-8CA8-177233469B9EQ47617473-C4277A36-E86D-4362-A343-3E52D1598F82Q47771695-11BBF0A3-30D0-4036-AFEB-F6B8D8D51D0CQ47853442-5AB45073-4F8D-4EC5-B5C3-AA203AAF85F3Q47899803-E1875514-540B-41E1-B7BC-88CC2B4F26BCQ48033863-01640F5E-7F69-47D7-9ACF-FFC4E486B99CQ48117662-DA183A18-5830-46AF-933D-23474E5A7324Q48307043-59FD6AEE-B471-47E6-BD0B-968CFEB355A0Q48402369-6AF7F03C-F9BF-42A8-BB6F-F20118D0A2D1Q48663479-9FB34871-EB75-4931-A6FD-749B7EA7D125Q49829513-1E789A2D-ECAF-419E-9B13-9F5B5E87387EQ49842640-30A01607-B84D-4E3B-9DAE-1586601606F2Q50041501-1D741861-4DB1-411B-857F-76300428E59DQ52562075-FF1302BF-4C69-4313-A622-3602292B1067Q52584624-8372A953-7122-4163-8FDA-7B3A6CDD06DBQ54935926-A785441B-E0C3-4E5A-AE9E-DD80BF300C78Q54948216-4401CC42-54CA-4E78-9369-DC29CE52FBA5Q55457298-4119EFBD-F1F2-4EA6-9B3F-A056905C37F7Q55457379-320C6F3B-C841-4CA4-8D04-B6DBE8B78C3C
P2860
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@ast
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@en
type
label
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@ast
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@en
prefLabel
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@ast
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@en
P2093
P2860
P50
P356
P1433
P1476
Integration of 2-hydroxyglutar ...... e dehydrogenase-mutant glioma.
@en
P2093
Alissa Thomas
Antonio A Omuro
Carl Campos
Changho Choi
Chuanhui Dong
Craig P Nolan
Dongwei Zhu
Elena Pentsova
Elizabeth Maher
Jamie Tisnado
P2860
P304
P356
10.1093/NEUONC/NOV307
P50
P577
2015-12-20T00:00:00Z